Advertisement

Archiv für Psychiatrie und Nervenkrankheiten

, Volume 232, Issue 3, pp 215–222 | Cite as

Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man

  • A. E. Balant-Gorgia
  • P. Schulz
  • L. Dayer
  • L. Balant
  • A. Kubli
  • C. Gertsch
  • G. Garrone
Article

Summary

We have measured the metabolites (demethylated and hydroxylated) of amitriptyline in a group of seven normal volunteers. They were phenotyped as extensive or poor metabolizers using debrisoquine and bufuralol. The results demonstrate that the oxidative metabolism (aliphatic hydroxylation) of amitriptyline is under the same genetic control as that of debrisoquine and bufuralol.

However, phenotypic polymorphism cannot be used to predict amitriptyline blood concentration after a single oral dose, since the principal metabolic pathway of amitriptyline is demethylation and not aliphatic hydroxylation.

Key words

Amitriptyline Nortriptyline Hydroxylated metabolites Oxidation polymorphism Hydroxylation polymorphism Pharmacogenetics Interindividual differences Pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alvan G, Von Bahre C, Seideman P, Sjöqvist F (1982) High plasma concentration of β-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet I:333CrossRefGoogle Scholar
  2. Balant L, Mc Ainsh J (1980) Use of metabolite data in the evaluation of pharmacokinetics and drug action. In: Jenner P, Testa P (eds) Concepts in drug metabolism. Marcel Dekker, New York, pp 311–371Google Scholar
  3. Baldessarini R (1980) Drugs and the treatment of psychiatric disorders. In: Goodman Gilman A, Goodman L, Gilman A (eds) The pharmacological basis of therapeutics, 6th edn. Mcmillan, New York, pp 391–447Google Scholar
  4. Dayer P, Courvoisier F, Balant L, Fabre J (1982a) Beta-blockers and drug oxidation status. Lancet I:509Google Scholar
  5. Dayer P, Balant L, Courvoisier F, Küpfer A, Kubli A, Gorgia A, Fabre J (1982b) The genetic control of bufuralol in man. Eur J Drug Metab Pharmacokin 7:33–77Google Scholar
  6. Dick B, Küpfer A, Molnar J, Braunschweig S, Preisig R (1982) Hydroxylierungs-Defekt für Medikamente (Typus Debrisoquin) in einer Stichprobe der Schweizer Bevölkerung. Schweiz Med Wochenschr 112:1061–1067PubMedGoogle Scholar
  7. Eichelbaum M (1982) Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clin Pharmacokin 7:1–22Google Scholar
  8. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183–187CrossRefPubMedGoogle Scholar
  9. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet II:584–586CrossRefGoogle Scholar
  10. Mellström B, Bertilsson L, Säwe J, Schulz HU, Sjöqvist F (1981) E and Z-10 hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 30:189–193PubMedGoogle Scholar
  11. Nebert DW (1981) Possible clinical importance of genetic differences in drug metabolism. Br Med J 283:537–542Google Scholar
  12. Pang KS, Rowland M (1978) Hepatic clearance of drugs. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokin Biopharmacol 5:625–633CrossRefGoogle Scholar
  13. Potter WZ, Calil JM, Sutfin TA, Zavadil AP, Jusko WJ, Rapoport J, Goodwin FK (1982) Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther 31:393–401PubMedGoogle Scholar
  14. Rollins D, Alvan G, Bertilsson L, Gillette J, Mellström B, Sjöqvist F, Traskman L (1980) Inter-individual differences in amitriptyline demethylation. Clin Pharmacol Ther 28:121–129PubMedGoogle Scholar
  15. Rowland M, Tozer TN (1980) Clinical Pharmacokinetics: Concepts and applications. Lea and Febiger, Philadelphia, p 331Google Scholar
  16. Rowland M, Benet LZ, Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokin Biopharmacol 1:123–136CrossRefGoogle Scholar
  17. Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL (1978) Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J 2:655–657PubMedGoogle Scholar
  18. Vandel B, Sandoz M, Vandel S, Allers G, Volmat R (1982) Biotransformation of amitriptyline in depressive patients: urinary excretion of seven metabolites. Eur J Clin Pharmacol 22: 239–245CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • A. E. Balant-Gorgia
    • 1
  • P. Schulz
    • 1
  • L. Dayer
    • 2
  • L. Balant
    • 2
  • A. Kubli
    • 1
  • C. Gertsch
    • 1
  • G. Garrone
    • 1
  1. 1.Department of PsychiatryUniversity of GenevaGeneva 4Switzerland
  2. 2.Department of MedicineUniversity of GenevaGeneva 4Switzerland

Personalised recommendations